LIVINGSTON, NJ--(Marketwired - February 10, 2016) -
Milestone Scientific Inc.'s
(NYSE MKT: MLSS) Epidural & Intra-Articular (IA) Subsidiary today announced that its abstract entitled "A randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of the epidural space verification with the CompuFlo® Epidural Computer Controlled System (CompuFlo)," has been accepted for presentation at the prestigious Euroanaesthesia 2016 Congress taking place May 28-30, 2016 in London.
The abstract was authored by Dr. Douglas Dobecki, Diplomate of the American Board of Anesthesiology and a double-board certified anesthesiologist and interventional pain management expert from the San Diego Pain Institute. The abstract will be published in the supplement of the European Journal of Anaesthesiology that will coincide with the meeting.
Milestone's Epidural & Intra-Articular (IA) Subsidiary designed the study in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess the safety and effectiveness of the pressure sensing technology in identification of the epidural space.
Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "We are pleased to announce the acceptance of an abstract regarding our epidural instrument in yet another leading anesthesia journal, this time in Europe, and look forward to presenting the findings at the Euroanaesthesia 2016 Congress in London."
About Milestone Scientific Inc.
Milestone Scientific Inc. (NYSE MKT: MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.